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ABSTRACT
Cytokines secreted by infiltrating immune cells
during atherogenesis modulate vascular remodel-
ing. One exemplary event is the antagonism
between transformed growth factor (TGF-b) and
interferon gamma (IFN-c) on the transcriptional con-
trol of type I collagen gene (COL1A2). Previously we
have reported that IFN-c up-regulates regulatory
factor for X-box B (RFXB) to repress collagen tran-
scription while down-regulates the expression
of RFXBSV, a splice variant of RFXB that blocks
collagen repression in fibroblasts. Here we demon-
strate that TGF-b abrogated COL1A2 repression by
IFN-c through altering the relative expression of
RFXB and RFXBSV. Unlike RFXB, RFXBSV did not
bind to the collagen promoter and competed with
RFXB for the co-repressor histone deacetylase
2 (HDAC2), limiting HDAC2 recruitment to the col-
lagen transcription start site as evidenced by chro-
matin immunoprecipitation assays. Over-expression
of RFXB by lentiviral infection in HASMCs enhanced
HDAC2 enlistment, promoted histone deacetylation
surrounding the collagen site by IFN-c, and blocked
the TGF-b antagonism, a pattern reversed by
RFXBSV infection. On the contrary, silencing of
RFXB, but not both RFXB and RFXBSV, expression
promoted the TGF-b antagonism. Thus, we have
identified a novel mechanism whereby TGF-b antag-
onizes the IFN-c repression of collagen transcription
in HASMCs and as such provided new insights into
antiatherogenic strategies.
INTRODUCTION
Atherosclerosis is a multi-factorial process highlighted
by a panel of inter-connected pathophysiological events.
The aggregation and activation of immune cells initiate
the formation in the arteries of an atherosclerotic lesion
(1). Later, medial smooth muscle cells (SMCs) encroach
into the intima synthesizing and depositing extracellular
matrix (ECM) proteins en route to reshape the vessel wall
(2), which ultimately leads to the maturation of the ather-
osclerotic plaque (atheroma). As the vasculature under-
goes active remodeling, inﬁltrating immune cells secret
cytokines to challenge SMCs and alter the synthesis of
ECM proteins. Over-production of ECM content thickens
the vessel wall and constrains the lumen, which impedes
the blood ﬂow resulting in cardiac ischemia. Atheroma
with reduced ECM content, on the other hand, is
prone to acute rupture causing myocardiac infarction.
Therefore, the interplay between various cytokines
and SMCs leads to deregulated ECM synthesis and
largely dictates the clinical complications associated with
arteriosclerosis.
Collagen type I is the most enriched ECM component
in the vasculature and is found in abundance in the
plaque, the levels of which aﬀect the vulnerability of the
plaque and correlate with the mortality and morbidity of
atherosclerosis (3,4). Collagen type I is a heterotrimer of
two alpha1 chains (COL1A1) and one alpha2 chain
(COL1A2), whose transcription is coordinately regulated
by various humoral factors in the plaque, among which
are interferon gamma (IFN-g) and transforming growth
factor (TGF-b). IFN-g and TGF-b, both of which are
primarily secreted by T lymphocytes and macrophages
in the plaque, often exhibit opposite characteristics
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T-cell activation and exacerbates inﬂammation, whereas
TGF-b is known to suppress the expression of a range
of pro-inﬂammatory molecules associated with atherogen-
esis (7–9). Interestingly, although both cytokines tend
to inhibit the proliferation of vascular SMCs, it is evident
that TGF-b strongly activates collagen transcription (10),
whereas IFN-g is a potent repressor of collagen synthesis
(11). Thus, IFN-g and TGF-b diﬀerentially modulate
the ﬁbrous content of the plaque, creating a converging
point where the stability of atheroma is regulated. The
mechanism underlying the antagonism between IFN-g
and TGF-b, however, is still a matter of controversy
(12–16).
Transcription of collagen type I is also ﬁne-tuned by a
group of proteins that ‘write’ the epigenetic information,
namely DNA and histone modifying enzymes (17,18).
Our earlier investigations have revealed that in ﬁbroblast
cells, IFN-g mediated repression of COL1A2 transcription
is accompanied by a decrease in histone acetylation
surrounding the transcription start site, occupied by the
trimeric regulatory factor for X-box (RFX) complex
consisting of RFX5, RFXB and RFXAP (19). The RFX
complex helps recruit a histone deacetylases 2 (HDAC2)-
containing co-repressor complex to the COL1A2 tran-
scription start site (20). Here we report that TGF-b
diﬀerentially regulates the expression of RFXB, which
interacts with HDAC2 and binds to the COL1A2 pro-
moter, and its splice variant RFXBSV, which interacts
with HDAC2 but does not bind to the COL1A2 promoter.
In doing, TGF-b interferes with RFX-dependent recruit-
ment of HDAC2 to and restores histone acetylation
around the collagen transcription start site. Thus, we
have identiﬁed a novel mechanism whereby TGF-b antag-
onizes the repression of COL1A2 transcription by IFN-g.
MATERIALS AND METHODS
Cell culture and treatment
Human aortic smooth muscle cells (HASMCs, Lonza)
were maintained in SMBM with supplements supplied
by the vendor. Human embryonic kidney cells (293FT,
Invitrogen) were grown in DMEM (Invitrogen) supple-
mented with 10% FBS (Hyclone). In certain experiments,
cells were treated with cytokines. Cells were switched to
0.4% media 16–24h prior to treatment. IFN-g (100U/ml,
Roche) and/or TGF-b (2ng/ml, R&D) were added and
maintained in 0.4% media for indicated time points.
Plasmids, transfection and viral infection
The col1a2-luciferase constructs pH20 ( 220/+54) and
pGL3-COL-LUC ( 357/+55) as well as the COL1A1-
luciferase construct ( 331/+114) were as previously
described (21–23). The FLAG-tagged expression con-
structs pcDNA3/FLAG-RFXB and pcDNA3/FLAG-
RFX5 were gifts from Dr Jenny Ting (24). pcDNA3/
FLAG-HDAC2 was kindly provided by Dr Edward
Seto (25). FLAG-RFXBSV was constructed by amplify-
ing the RFXBSV cDNA from pRFXB5 (26) and
re-ligating the insert into pcDNA3/FLAG. The lentiviral
constructs pLenti6/V5-RFXBSV and pLenti6/V5-RFXB
were constructed similarly. All plasmids were veriﬁed by
restriction digestion and direct sequencing. Transfections
were performed with Lipofectamine 2000 (Invitrogen).
Luciferase activities were measured using a luciferase
reporter assay system (Promega). Experiments were rou-
tinely performed in triplicate wells and repeated three
times. Lentivirus carrying the expression constructs
pLenti6/V5-RFXB and pLenti6/V5-RFXBSV was gener-
ated in 293FT cells as previously described (27). Cells were
harvested 48h after infection.
Whole-cell protein extraction and co-immunoprecipitation
Whole-cell lysates were obtained as previously described
(20). FLAG-conjugated beads (M2, Sigma) were added to
and incubated with 500mg protein lysates overnight.
Precipitated immune complex was eluted with 3X FLAG
peptide (Sigma). Western blot analyses were performed
with monoclonal anti-FLAG (Sigma), polyclonal anti-
RFX5 (Rockland), polyclonal anti-HDAC2 (Santa
Cruz), monoclonal anti-b-actin (Sigma), monoclonal
anti-V5 (Sigma) and polyclonal anti-collagen type I
(Rockland) antibodies.
Nuclear protein extraction and DNA affinity pull-down
Nuclear protein extracts were obtained essentially as
previously described (20). A piece of double-stranded col-
lagen DNA oligos was used as the probe (COL1A2 25/
+30, Genbank accession number AF004877) (28). In vitro
DNA aﬃnity pull-down assays were performed as pre-
viously described (20). Brieﬂy, pre-cleared nuclear proteins
were incubated with biotin-labeled DNA probe. DNA–
protein complex formed was then captured by incubating
with the streptavidin beads on a shaking platform.
Ternary complex (biotin-labeled DNA–protein–streptavi-
din) was washed extensively and eluted with 1  SDS
electrophoresis sample buﬀer and analyzed by Western
blot analysis. Competition of binding was performed
with speciﬁc as well as non-speciﬁc DNA oligos as pre-
viously described (20).
RNA extraction and real-time PCR
RNA was extracted using an RNeasy RNA isolation kit
(Qiagen). Reverse transcriptase reactions were performed
using a SuperScript First-strand synthesis system
(Invitrogen). Real-time PCR reactions were performed
on an ABI Prism 7500 (Applied Biosystems). The oligo-
nucleotide forward and reverse PCR primers and ﬂuores-
cent probes for RFXB, RFXBSV, collagen type I and
HLA-DRa were as previously described (20). SM22a
primer/probe set was purchased from Applied Biosystems.
Chromatin immunoprecipitation (ChIP)
ChIP analyses were performed essentially as described
before (19). Aliquots of cell lysates containing 200mgo f
protein were used for each immunoprecipitation reaction
with anti-RFX5 (Rockland), anti-HDAC2 (Santa Cruz),
anti-acetylated H3 (Millipore), anti-V5 (Sigma) and anti-
FLAG (Sigma) antibodies. Precipitated DNA was
4394 Nucleic Acids Research, 2009, Vol. 37,No. 13dissolved in 50ml deionized distilled water and 10ml was
used for each real-time PCR reaction. The primers sur-
rounding the collagen start site for real time PCR have
been described previously (19). Serial dilutions of genomic
DNA extracted from normal cells were included with
ChIP samples as standards to determine the amount
of DNA being precipitated by a particular antibody.
Ten percent of the starting material was also included as
the input. Data were normalized to input and expressed as
pg of DNA precipitated per ng of input DNA.
Short hairpin RNA (shRNA)-mediated silencing
The procedure for the construction of RFXB shRNA
plasmid (designated shB herein) and RFXB/RFXBSV
shRNA plasmid (designated shB/SV herein) was described
before (27). Brieﬂy, designing of reverse primers
(Supplementary Data Table I) was facilitated by the
Cold Spring Harbor RNAi oligo retriever program
(katahdin.cshl.org:9331/RNAi/html/rnai.html). PCR pro-
ducts were puriﬁed and ligated into pLenti6-V5-TOPO
vector using a Viralpower directional cloning kit
(Invitrogen). Positive clones were veriﬁed by direct
sequencing. Silencing was performed by infecting
HASMCs with diﬀerent viral plasmids (shB or shB/SV)
as described earlier (27).
Statistical analysis
One-way ANOVA with post-hoc Scheﬀe analyses were
performed using an SPSS package. P-values <0.05 were
considered statistically signiﬁcant.
RESULTS
TGF-b blocks the repression of COL1A2 transcription
by IFN-c while altering the relative expression of
RFXB/RFXBSV in HASMCs
We ﬁrst examined the expression of collagen type I in
human primary aortic smooth muscle cells (HASMCs)
with IFN-g and/or TGF-b treatment. IFN-g potently
down-regulated both mRNA levels (Figure 1A and B)
and protein levels (Figure 1C) of collagen type I, which
was completely abrogated by TGF-b treatment, in line
with ﬁndings observed in other cell types (15,29,30).
Antagonism between IFN-g and TGF-b on collagen syn-
thesis primarily occurred at the transcriptional level as
judged by promoter-reporter assays. IFN-g repressed the
activities of two COL1A2 promoter-reporter constructs as
well as one COL1A1 construct in HASMCs (Figure 1D).
Although TGF-b up-regulated the activities of three pro-
moter constructs with various magnitude, it abolished the
repression by IFN-g similarly and comparable to changes
in message as well as protein levels of type I collagen.
Previous investigations indicate that IFN-g promotes
RFXB expression while suppressing RFXBSV expression
in HEK293 cells (31) and lung ﬁbroblast cells (19). In
SMCs, IFN-g augmented RFXB expression and reduced
RFXBSV expression simultaneously in a time-dependent
manner, in agreement with previous reports (Figure 2A
and B). TGF-b alone marginally altered the expression
of both RFXB and RFXBSV without statistical signiﬁ-
cance. However, TGF-b abolished the induction of
RFXB expression and repression of RFXBSV expression
by IFN-g, suggesting that diﬀerential expression of RFXB
isoforms may play a role in the antagonism between
IFN-g and TGF-b. As a control, message levels of
RFX5, another component of the RFX complex, were
stimulated by IFN-g but unopposed by TGF-b under
the same condition (Figure 2C).
RFXB alleviates the antagonism of IFN-c mediated
collagen transcription repression by TGF-b
Since we observed an alteration in the relative expression
of RFXB versus RFXBSV during the TGF-b antagonism
of IFN-g mediated repression of collagen synthesis, the
individual roles of RFXB and RFXBSV were probed in
HASMCs. First, consonant with our previous report,
over-expression of RFXB enhanced IFN-g repression of
COL1A2 promoter activity. Increasing concentrations of
RFXBSV, however, abrogated the IFN-g repression and
antagonized the enhancement by RFXB in SMCs
(Figure 3A). Next, the antagonism between TGF-b and
IFN-g on COL1A2 transcription was examined in the
presence of ectopically expressed RFXB or RFXBSV.
When RFXB was over-expressed, the reversion of IFN-g
repression by TGF-b was substantially inhibited
(Figure 3B). On the other hand, RFXBSV signiﬁcantly
promoted the TGF-b antagonism when it was present in
excess. Finally, SMCs were infected with viral particles
carrying either RFXB or RFXBSV and endogenous
COL1A2 message and protein levels were examined.
RFXB restored the repression of endogenous collagen
expression by IFN-g in the presence of TGF-b
(Figure 3C and D). RFXBSV, however, not only sup-
pressed the repression of collagen synthesis by IFN-g,
but further reinforced the antagonism by TGF-b.T o
rule out the possibility that these observations were arti-
fact caused by RFXB/RFXBSV over-expression, the tran-
scription of HLA-DRa, which faces the same competition
between IFN-g and TGF-b 32, was examined by promo-
ter-luciferase and quantitative PCR assays. Unlike col-
lagen type I gene, the antagonism between IFN-g and
TGF-b on HLA-DRa transcription was not aﬀected by
infection of either RFXB or RFXBSV (Supplementary
Data Figure 1). Together, these data suggest that RFXB
and RXBSV had opposite roles in the regulation of
collagen synthesis. Moreover, relative expression of
RFXB and RFXBSV also determined the balance
of antagonism between IFN-g and TGF-b.
RFXB and RFXBSV compete for the binding of HDAC2
thus limiting its recruitment to the collagen
transcription start site
Our earlier ﬁndings suggest that RFXB forms a complex
with RFX5 and recruits HDAC2 to the collagen pro-
moter, which in turn deacetylates core histones and
represses transcription of collagen type I in response to
IFN-g (19,20). Therefore, we examined whether RXBSV
existed in a similar complex with RFX5 and HDAC2.
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Figure 1. TGF-b blocks the repression of COL1A2 transcription by IFN-g in HASMCs. (A, B) HASMCs were treated with IFN-g and/or TGF-b for
various time points as indicated. Collagen type I message levels were measured by real-time PCR. Data are expressed as relative RNA levels
compared to control levels, normalized to 18S RNA and presented as average   SD. (C) HASMCs were treated with IFN-g and/or TGF-b, and
measured for collagen protein levels by Western blot. A representative picture is shown. Normalized collagen levels were compared to the control
group and expressed as relative densitometric values. Shown in the graph are data collected from three independent experiments and expressed as
average   SD. (D) HASMCs were transfected with diﬀerent collagen type I promoter constructs along with GFP for normalization. Cells were
treated with IFN-g and/or TGF-b 24h after transfection. Luciferase activities were assayed 48h after transfection, normalized by both protein
concentration and GFP ﬂuorescence, and presented as average   SD.
4396 Nucleic Acids Research, 2009, Vol. 37,No. 13First, V5-tagged RFXB or RFXBSV was co-transfected
with FLAG-tagged RFX5 or HDAC2 into HEK293
cells followed by immunoprecipitation with an anti-V5
antibody to examine the interactions. As shown in
Figure 4A, both RFXB and RFXBSV came down along
with HDAC2 (bottom and middle panels). Interestingly,
unlike RFXB, RFXBSV failed to interact with RFX5
(top panel).
Next, in order to determine whether RFXB and
RFXBSV could bind to COL1A2 transcription start
site and recruit HDAC2, nuclear proteins extracted from
HEK293 cells transfected with either FLAG-tagged
RFXB or RFXBSV were incubated with a biotin-
labeled collagen probe. Both RFX5 and HDAC2 were
present on the collagen site without ectopically expressed
RFXB or RFXBSV (Figure 4B, lane 2). The bindings
were eliminated by a speciﬁc competitor for RFX5
(X-box, lane 3) but not by a non-speciﬁc competitor
(Sp1, lane 4), suggesting that recruitment of HDAC2
relied on RFX5. Over-expressed exogenous RFXB
was able to bind to the collagen site (lane 6) and slightly
increased the bindings of both RFX5 and HDAC2
(compare lane 6 to lane 2). On the other hand,
RFXBSV was not associated with the collagen probe.
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Figure 2. TGF-b alters the relative expression of RFXB splice variants in response to IFN-g in HASMCs. HASMCs were treated with IFN-g and/or
TGF-b. Message levels of RFXB (A), RFXBSV (B) and RFX5 (C) were measured by real-time PCR.
Nucleic Acids Research, 2009,Vol.37, No. 13 4397Moreover, over-expression of RFXBSV down-regulated
the binding of RFX5 and HDAC2 (compare lane 10 to
lane 2). Similar results were also observed in physiologi-
cally relevant HASMCs infected with viral clones carrying
either V5-RFXB or V5-RFXBSV (Figure 4B, bottom
panel).
Next, in order to evaluate the binding capacity of
RFXB and RFXBSV as well as their ability to promote
the recruitment of HDAC2 to the endogenous COL1A2
start site, ChIP analyses were performed. Consistent with
the in vitro DNA aﬃnity pull-down assay, RFXB but
not RFXBSV was bound to the endogenous collagen
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Figure 3. RFXB alleviates the antagonism of IFN-g mediated collagen transcription repression by TGF-b.( A) A collagen type I promoter construct
(pH 20) was co-transfected with expression constructs for RFXB and/or RFXBSV into HASMCs. IFN-g was added 24h after transfection and
incubated with cells for additional 24h. Luciferase activities were normalized by both protein concentration and GFP ﬂuorescence, and presented as
average   SD. (B) A collagen type I promoter construct (pH 20) was co-transfected with expression constructs for RFXB and/or RFXBSV into
HASMCs as indicated. Cells were treated with IFN-g and/or TGF-b for 24h. Data were obtained and analyzed as described under (A). (C, D)
HASMCs were infected with lentiviral stocks carrying an empty vector (pLenti6/V5), RFXB or RFXBSV as indicated. Cells were treated with IFN-g
and/or TGF-b 24h after infection. RNA or protein was extracted 24h after treatment. Message (C) and protein (D) levels of collagen type I were
assessed by real-time PCR and Western blot, respectively. Data were processed and presented as described in Figure 1.
4398 Nucleic Acids Research, 2009, Vol. 37,No. 13promoter (Figure 4C). More importantly, more HDAC2
(1.5X) and RFX5 (1.3X) were found to be associated
with the same site when there was an over-expression
of RFXB. On the contrary, when RFXBSV was over-
expressed, there was a signiﬁcant decrease in the binding
of HDAC2 and RFX5. In addition, stimulation of recruit-
ment of HDAC2 as well as RFX5 by RFXB was blunted
by RFXBSV. Similarly, over-expression of RFXBSV by
viral infection in HASMCs dampened the recruitment
of RFX5 and HDAC2 to the collagen promoter,
whereas over-expression of RFXB promoted the binding
of RFX5 and HDAC2, and relieved the antagonism
by RFXBSV (Figure 4D). To verify whether altered
HDAC2 recruitment by RFXB/RFXBSV was speciﬁc
to the collagen promoter, the binding of HDAC2 to the
promoter of SM22a, an SMC marker gene whose tran-
scription is regulated by HDAC2 (33), was examined.
Indeed, HDAC2 was associated with the SM22a promoter
A
B
Figure 4. RFXB and RFXBSV compete for the binding of HDAC2, thus limiting its recruitment to the collagen transcription start site. (A) 293FT
cells were transfected with V5-tagged RFXB or V5-tagged RFXBSV along with either FLAG-tagged RFX5 or FLAG-tagged HDAC2.
Immunoprecipitations were performed as described under ‘Materials and Methods’. Ten percent of the starting material was also loaded as input.
(B) 293FT cells were transfected with FLAG-tagged RFXB, FLAG-tagged RFXBSV or an empty vector (top panel). Alternatively, HASMCs were
infected with pLenti/V5-RFXB, pLenti/V5-RFXBSV or an empty vector (bottom panel). DNA aﬃnity pull-down assays were performed as described.
Binding of RFX5 and HDAC2 to the collagen probe in the presence of RFXB and RFXBSV was normalized to the control group and expressed as
relative binding aﬃnity. Shown in the graph are data collected from three independent experiments and expressed as average   SD. (C, D) 293FT cells
were transfected with FLAG-tagged RFXB and/or FLAG-tagged RFXBSV (C). Alternatively, HASMCs were infected with pLenti/V5-RFXB and/or
pLenti/V5-RFXBSV (D). Chromatin immunoprecipitation assays were performed with anti-RFX5, anti-HDAC2, anti-FLAG, anti-V5 or pre-immune
IgG as indicated. Precipitated DNA was ampliﬁed by real-time PCR with primers spanning the COL1A2 transcription start site ( P<0.05). (inset)
10% of the IP samples were separated by SDS-PAGE gels and examined for precipitation eﬃciency with Western blot. (E) A collagen type I promoter
construct (pH 20) was co-transfected with expression constructs for RFXB, RFXBSV or HDAC2 into HASMCs. Luciferase activities were normal-
ized by both protein concentration and GFP ﬂuorescence, and presented as average   SD ( P<0.05).
Nucleic Acids Research, 2009,Vol.37, No. 13 4399in ChIP assays (Supplementary Data Figure 2). Neither
RFXB nor RFXBSV over-expression impacted the bind-
ing of HDAC2 or SM22a mRNA levels.
Finally, we examined the functional relevance of
the interactions among RFXB, RFXBSV and HDAC2
on collagen transcription. As shown in Figure 4E,
RFXB and HDAC2 repressed collagen promoter activity
both singularly and synergistically when added together,
whereas RFXBSV by itself activated the promoter
slightly. More signiﬁcantly, RFXBSV counteracted the
repression of the collagen promoter activity by RFXB
and HDAC2. Combined, these data suggest that
RFXBSV interacted with HDAC2 but not with RFX5,
thus competing for the cellular pool of HDAC2 that
could be recruited to the collagen promoter by the
RFX5/RFXB complex to repress collagen transcription.
TGF-b blocks the recruitment of HDAC2 by IFN-c
and restores acetylation of core histones at the
collagen transcription start site
Previously we have reported that IFN-g represses collagen
transcription by down-regulating levels of histone acetyla-
tion around the COL1A2 transcription start site through
the recruitment of HDAC2 in lung ﬁbroblast cells (19,20).
Since we observed that the association of HDAC2 with
the collagen promoter was regulated by the relative
expression of RFXB and RFXBSV, we decided to assess
the possibility that TGF-b opposed the IFN-g repression
by blocking the recruitment of HDAC2, thus up-regulat-
ing histone acetylation. As expected, IFN-g treatment
led to a decrease in the acetylation of core histones
(Figure 5A and data not shown) accompanied by a
C
E D
Figure 4. Continued.
4400 Nucleic Acids Research, 2009, Vol. 37,No. 13concurrent increase of HDAC2 recruitment (Figure 5B) in
HASMCs. TGF-b alone did not have any signiﬁcant
impact on the histone acetylation or HDAC2 binding.
Nor did it aﬀect the histone acetylation by a large
margin, suggesting that TGF-b may activate collagen
synthesis through mechanisms other than blocking
HDAC2-mediated histone deacetylation. It did, however,
ameliorate the inhibition of histone acetylation and pre-
vent the induction of HDAC2 enlistment by IFN-g
Introduction into HASMCs exogenous RFXB led to fur-
ther decrease in histone acetylation and increased HDAC2
recruitment by IFN-g. It also completely blocked the
TGF-b induced antagonism of HDAC2 binding and his-
tone deacetylation (Figure 5A and B). RFXBSV, on the
other hand, disrupted the change in histone acetylation
and HDAC2 binding initiated by IFN-g and substantiated
the TGF-b antagonism. As a control, we also examined
the binding of RFX5 to the collagen transcription start
site under the same conditions. IFN-g markedly increased
the level of RFX5 associated with the collagen site, which
was only slightly decreased by TGF-b. RFXB infection led
to additional RFX5 binding, whereas RFXBSV infection
resulted in a decrease in RFX5 binding, both of which
relied on the presence of IFN-g. Nonetheless, the changes
in RFX5 binding were much milder than those of either
HDAC2 binding or histone acetylation. More impor-
tantly, when HDAC2 was over-expressed in HASMCs,
the TGF-b antagonism of collagen transcriptional repres-
sion by IFN-g was greatly alleviated (Figure 5D).
On the contrary, knock-down of HDAC2 expression sig-
niﬁcantly enhanced the antagonism of TGF-b on the
down-regulation of histone acetylation around COL1A2
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Figure 5. TGF-b blocks the recruitment of HDAC2 and restores the acetylation of core histones at the collagen transcription start site. (A–C)
HASMCs were infected with V5-tagged RFXB or V5-tagged RFXBSV or an empty vector followed by treatment with IFN- g and/or TGF-b as
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Nucleic Acids Research, 2009,Vol.37, No. 13 4401transcription start site as well as COL1A2 repression by
IFN-g (Supplementary Data Figure 3). Collectively, these
data indicate that the antagonism between IFN-g and
TGF-b on collagen transcription manifests, at the chro-
matin level, as alterations in HDAC2 binding and histone
acetylation around the collagen transcription start site,
which are mediated by the relative expression of RFXB
and RFXBSV.
Silencing of RFXB expression favors the TGF-b antagonism
of IFN-c induced collagen repression
To further probe the role of RFXB and its splice variant
in mediating the antagonism between IFN-g and TGF-b,
the following strategy was employed. Because RFXB and
RFXBSV share substantial sequence identity, our attempt
to silence them individually was not successful. Through
extensive screening, we obtained two plasmids expressing
shRNA: one targets RFXB only (shB), whereas the other
targets both RFXB and RFXBSV (shB/SV). Speciﬁcity
and eﬃciency of these two plasmids were veriﬁed by
western blot (Figure 6A) and quantitative PCR
(Supplementary Data Figure 4). Infection of HASMCs
with viral stocks carrying shB led to further antagonism
of IFN-g induced collagen repression by TGF-b
(Figure 6B and C), indicating that the balance between
IFN-g and TGF-b relies on the relative expression of
RFXB and RFXBSV. Infection with shRNA targeting
both RFXB and RFXBSV, however, had no such eﬀect,
suggesting that a new balance could be established
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Figure 6. RFXB silencing favors the TGF-b antagonism of IFN-g induced collagen repression. (A) HEK293 cells were transfected with FLAG-
tagged RFXB or RFXBSV plasmids in the presence of shB, shB/SV or an empty vector (EV). Silencing eﬃciency was measured by Western blot.
(B, C, D) HASMCs were infected with viral stocks carrying shB, shB/SV or an EV followed by treatment with IFN-g and/or TGF-b as indicated.
Message (B) and protein (C) levels of collagen type I were assessed by real-time PCR and Western blot, respectively as described in Figure 1. ChIP
assays (D) with anti-AcH3, -HDAC2 and –RFX5 antibodies were performed as described in Figure 5. (E) A collagen type I promoter construct (pH
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with IFN-g and/or TGF-b. Luciferase activities were normalized by both protein concentration and GFP ﬂuorescence, and presented as average
  SD ( P<0.05).
4402 Nucleic Acids Research, 2009, Vol. 37,No. 13between IFN-g and TGF-b once both RFXB and
RFXBSV were removed. Similar changes were observed
on the collagen chromatin where RFXB silencing resulted
in additional decrease in HDAC2 binding and increase in
histone H3 acetylation compared to control or silencing of
both RFXB and RFXBSV (Figure 6D). Finally, enhanced
TGF-b antagonism, brought by RFXB silencing, of IFN-
g induced repression of collagen promoter was alleviated
by the presence of HDAC2 (Figure 6E), again indicating
the competition converges on HDAC2 that is available
inside the cell.
DISCUSSION
It has long been documented that collagenous content
in atheroma contributes to the overall susceptibility of
atherosclerosis, highlighting the importance of regulation
of collagen levels during atherogenesis (34). Here we
examined the possible mechanism underlying the antago-
nism between IFN-g and TGF-b on the transcriptional
regulation of collagen type I (COL1A2) in human aortic
smooth muscle cells. Our data suggest that TGF-b inter-
feres with the diﬀerential expression of RFXB and its
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Nucleic Acids Research, 2009,Vol.37, No. 13 4403splice variant RFXBSV induced by IFN-g, thus abrogat-
ing HDAC2-dependent histone deacetylation surrounding
the collagen transcription start site.
IFN-g and TGF-b are two major cytokines found in the
atherosclerotic plaque that modulate the expression of
collagen. Whereas IFN-g suppresses collagen production
and renders the plaque prone to rupture, TGF-b sti-
mulates collagen synthesis and stabilizes the plaque (35).
The mechanism underneath the antagonism between
IFN-g and TGF-b on collagen production has been
tackled on by several independent groups under diﬀerent
circumstances, mostly in ﬁbroblast cells to study ﬁbrosis.
For instance, it has been proposed that IFN-g-induced
Stat-1 sequesters an essential transcription activator,
either AP-1 (14) or CBP/p300 (15), that is required for
TGF-b dependent transcriptional activation of collagen
type I. Alternatively, YB-1, another protein up-regulated
by IFN-g, either competes for the binding of CBP/p300
(12) or stimulates the expression of the inhibitory TGF-b
mediator Smad7 (13), thus dampening the ﬁbrogenic
eﬀect of TGF-b Another possible scenario involves
direct inhibition of TGF-b synthesis by IFN-g in human
primary skin ﬁbroblast cells (16). Notably, these studies all
concentrate on the more distal promoter region where
TGF-b has a much stronger response of activation
(presumably through stimulating Smad binding). It is evi-
dent, however, that even on shorter promoter constructs,
where TGF-b only marginally activates collagen transcrip-
tion, TGF-b is still capable of blanking the repression by
IFN-g (Figure 1D, compare the three collagen promoter
constructs of diﬀerent sizes), indicating that at least part
of the antagonism may be mediated by factors that bind to
the proximal and/or start site of the collagen promoter.
Indeed, TGF-b blocks the up-regulation of RFXB
(Figure 2A), which binds to the collagen transcription
start site and recruits HDAC2 when complexed with
RFX5 and RFXAP to mediate the IFN-g eﬀect (19,20)
Furthermore, TGF-b also restores the expression of
RFXBSV (Figure 2B), a naturally occurring splice variant
of RFXB (26). Thus, TGF-b antagonizes the repression
by IFN-g through manipulating the molecular events
surrounding the COL1A2 transcription start site.
Previously, we have demonstrated that RFX5 interacts
with HDAC2 and enlists it to the collagen transcription
start site in response to IFN-g (20). Our new data sum-
marized here suggest that both RFXB and RFXBSV are
associated with HDAC2 (Figure 4A). RFXBSV, however,
does not interact with RFX5 (Figure 4A) and fails to bind
to the COL1A2 transcription start site (Figure 4B–D).
Furthermore, in the presence of excessive RFXBSV the
RFXB RFXBSV RFXBSV
IFN-
+ -
TGF-
HDAC2
RFX5
COL1A2 transcription start site
HDAC2
X repression
nucleus
Zone 1 (COL1A2)
HDAC2
HDAC2HDAC2 X
Zone 2 (SM22 )
Figure 7. A schematic representation of proposed model for RFXB variants mediated antagonism between IFN-g and TGF-b in collagen type I
transcription. IFN-g stimulates the production of RFXB, which interacts with RFX5 and recruits HDAC2 to the COL1A2 start site (in a specialized
sub-nuclear ‘zone’) to repress transcription. Meanwhile, IFN-g down-regulates the levels of RFXBSV, which does not interact with RFX5 and fails
to bind to the COL1A2 start site, thus squelching HDAC2 away and alleviating the repression. TGF-b antagonizes IFN-g induced COL1A2
repression by reshuﬄing the balance between RFXB and RFXBSV through diﬀerential regulation of their expression. In a separate ‘zone’ where
SM22a gene is located, HDAC2 binds to the promoter more strongly and is immune from the squelching by RFXBSV.
4404 Nucleic Acids Research, 2009, Vol. 37,No. 13binding of HDAC2 as well as RFX5 to the collagen site is
hindered (Figure 4B–D). Thus, it appears that there are at
least two reservoirs of HDAC2 complex inside the cell.
One contains RFXB that binds to the collagen site to pro-
mote histone deacetylation and hence transcriptional
repression by IFN-g (Figures 5 and 6). The other contains
RFXBSV that ‘stays clear’ the collagen site and impedes
the formation and/or promoter recruitment of the alter-
native complex, abrogating the repression of collagen
transcription by IFN-g (Figures 5 and 6).
One major pitfall with the current model of
HDAC2-squelching presented here (Figure 7) is how the
ratio of RFXB versus RFXBSV, by itself, could eﬀectively
control the nuclear pool of HDAC2, a common co-factor
with seemingly unlimited availability. This discrepancy
can be reconciled by several possible explanations. Type
I collagen gene has been mapped to discrete sites in the
nucleus by ﬂuorescent immuno-in-situ hybridization
(FISH) (36). Indeed, it has been demonstrated that indi-
vidual transcriptional events do not occur at random
sub-nuclear compartments. Instead, actively transcribed
genes are found at various highly organized foci in the
nucleus (37). Presumably, RFXBSV and RFXB (and a
portion of all the available HDAC2 in the nucleus) are
conﬁned to a speciﬁc ‘zone’, where collagen transcription
is taking place. Therefore, within the speckle, HDAC2
availability becomes a rate-limiting factor that can be
modulated by the diﬀerential expression of RFXB and
RFXBSV. Alternatively, since recruitment of HDAC2 is
only observed on the collagen promoter, but not on the
SM22a promoter, we propose that the ability of HDAC2
to be sequestered is reliant on its aﬃnity for diﬀerent
promoters. It is possible that HDAC2 binds with higher
aﬃnity to some promoters (e.g. SM22a, likely through
stronger protein–protein interactions with SM22a-speciﬁc
transcription factors) than to others (e.g. COL1A2), ren-
dering it less susceptible to squelching by increasing levels
of RFXBSV. Yet a third possibility exists that the impact
exerted by the decrease in the recruitment of HDAC2 to
the collagen promoter is multifold. In addition to aﬀecting
the chromatin environment surrounding the COL1A2
transcription start site, HDAC2 could ﬁne-tune the post-
translational modiﬁcations (PTMs) of key protein(s)
involved the repression of collagen transcription. In fact,
our previous publication suggests that the acetylation level
of RFX5 is regulated by HDAC2, which directly contrib-
utes to the COL1A2 repression (3) (It also needs to be
pointed out that target proteins for HDAC2-mediated
deacetylation that are involved in the COL1A2 repression
may not be limited to RFX5). Deacetylatoin of RFX5 by
HDAC2, in turn, may result in an increase of HDAC2
recruitment via enhanced protein–protein interactions.
Consequently, HDAC2 may facilitate the formation of
a multi-protein repression complex on the collagen pro-
moter, by modifying the overall chromatin structure and
acetylation status of individual transcription factors, ful-
ﬁlling its role in the IFN-g induced repression of COL1A2
transcription. Thus, although RFXBSV-mediated down-
regulation of HDAC2 recruitment may be inadequate by
itself to induce signiﬁcant changes in collagen transcri-
pion, later events (e.g. up-regulation of RFX5 acetylation
and release of HDAC2 from the COL1A2 promoter
due to reduced aﬃnity) nonetheless could operate in a
self-sustainable manner to amplify the original signal
such that de-repression of COL1A2 transcription can be
achieved. Of note, these scenarios are not necessarily
exclusive. For instance, the distinct aﬃnity of HDAC2
for diﬀerent promoters may well determine its sub-nuclear
localizations and ultimately, its availability. Further inves-
tigations are warranted to explore these possibilities.
In conclusion, we have identiﬁed here a novel mecha-
nism whereby TGF-b antagonizes the transcriptional
repression of collagen type I gene (COL1A2) by IFN-g
in human aortic smooth muscle cells (Figure 7). Since
TGF-b is also known to attenuate the up-regulation of
MHC II expression and antigen-dependent T-cell activa-
tion by IFN-g (38–40), it is possible that a similar mech-
anism involving a diﬀerent set of co-factors (instead of
HDACs) applies. Intriguingly, a recent study by Cunha
et al. reports that alternative splicing of the human ANK2
gene, closely related to RFXB, is implicated in cardiac
function (41). Thus, post-transcriptional processing
could be a shared feature among ankyrin proteins, allud-
ing to the importance of this regulatory dimension in
maintaining the physiological integrity of the cardiovascu-
lar system. Therefore, modulation of alternative splicing
and diﬀerential expression of RFXB isoforms may
present as a potential target for therapeutics against
atherosclerosis.
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